Polypharmacy among people diagnosed with colorectal cancer in Australia: a population-based cohort study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf380 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Oncologist, 2025. Verfasst von Benjamin Daniels und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Intelligence Research Program, School of Population Health, UNSW Sydney, Sydney, NSW 2052, Australia. Hauptthemen laut MEDLINE: Polypharmacy, Colorectal Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence, UNSW Research Infrastructure Scheme, Cancer Institute New South Wales Early Career Fellowship.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Background
Polypharmacy is associated with increased risks of adverse outcomes in people with cancer and medicine use evolves over the course of the disease trajectory. We estimated the prevalence of polypharmacy in people with colorectal cancer (CRC), stratified by extent of disease spread at diagnosis, during each year from one year prior to five years following diagnosis and determined factors associated with polypharmacy at diagnosis and two and five years post-diagnosis. Patients and Methods Our retrospective cohort study used linked administrative health records from New South Wales (NSW), Australia to examine medicine use in all NSW residents ≥18 years diagnosed with CRC between 2013-2017. We defined polypharmacy as concomitant exposure to ≥ 5 medicines, excluding antineoplastics, during at least one 90-day quarter in each year from diagnosis. We used logistic regression to examine associations between polypharmacy and relevant factors.
Results
Of 19,056 people diagnosed with CRC, 6,797 (35%), 8,482 (45%), and 3,777 (20%) were diagnosed with localised, regional, and metastatic disease, respectively. Within these groups, 74%-79% experienced polypharmacy at any time during the study period; with nearly 50% experiencing polypharmacy two through five years from diagnosis. Age (≥70 years), female sex, comorbidities, colon cancer diagnosis, and socioeconomic disadvantage were associated with increased likelihood of polypharmacy at all landmarks.
Conclusion
Polypharmacy is highly prevalent among Australians with CRC. For those treated with curative intent, higher polypharmacy rates are concerning, indicating excess morbidity and impaired quality of life among survivors cured of cancer but who may continue to experience poorer health than the general population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicines Intelligence Research Program, School of Population Health, UNSW Sydney, Sydney, NSW 2052, Australia.
- Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW 2052, Australia.
- School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW 2052, Australia.
- Maitland Hospital, Hunter New England Local Health District, NSW 2323, Australia.
- Hunter Medical Research Institute, University of Newcastle, NSW 2305, Australia.
- School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.
ORCID-Profile: Benjamin Daniels, Sallie-Anne Pearson
Förderung
- National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence
- UNSW Research Infrastructure Scheme
- Cancer Institute New South Wales Early Career Fellowship
Zitieren
APA
Daniels, B., Tang, M., Aslam, M., & Pearson, S. A. (2025). Polypharmacy among people diagnosed with colorectal cancer in Australia: a population-based cohort study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf380
Vancouver
Daniels B, Tang M, Aslam M, Pearson SA. Polypharmacy among people diagnosed with colorectal cancer in Australia: a population-based cohort study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf380
BibTeX
@article{Daniels2025,
author = {Daniels, Benjamin and Tang, Monica and Aslam, Maria and Pearson, Sallie-Anne},
title = {Polypharmacy among people diagnosed with colorectal cancer in Australia: a population-based cohort study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf380}
}
EUVIMED